Added to YB: 2026-09-24
Pitch date: 2026-09-20
CMPX [bullish]
Compass Therapeutics, Inc.
-37.77%
current return
Author Info
No bio for this author
Company Info
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
Market Cap
$342.2M
Pitch Price
$1.88
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.16
P/E
-4.70
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Sunday Week Ahead: September 21–27, 2026 - Compass Therapeutics, Inc.
CMPX: Compass Therapeutics’ tovecimig produced an 18.0% response rate versus 5.3% for control and 4.7 months of progression-free survival versus 2.6 months in second-line biliary tract cancer, yet shares remain at $1.89 amid crossover-clouded overall survival. Buy a full position ahead of FDA feedback this quarter and the October 24 ESMO presentation; risks are demands for cleaner survival data or a new confirmatory design and the small initial indication.
Read full article (1 min)